Dexmethylphenidate Hydrochloride
Generic Name: dexmethylphenidate hydrochloride
Brand Names:
Dexmethylphenidate Hydrochloride Extended-release
Dexmethylphenidate hydrochloride is the pharmacologically active d-enantiomer of racemic methylphenidate. The extended-release capsule provides a bi-modal release profile with half the dose as immediate-release beads and half as enteric-coated, delayed-release beads.
Overview
Dexmethylphenidate hydrochloride is the pharmacologically active d-enantiomer of racemic methylphenidate. The extended-release capsule provides a bi-modal release profile with half the dose as immediate-release beads and half as enteric-coated, delayed-release beads.
Uses
Indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older as a central nervous system stimulant.
Dosage
Oral administration once daily in the morning. Capsules may be swallowed whole or opened and contents sprinkled on applesauce. Pediatric starting dose: 5 mg daily. Adult starting dose: 10 mg daily. Titrate weekly in 5 mg increments (pediatrics) or 10 mg increments (adults). Maximum: 30 mg/day pediatrics, 40 mg/day adults.
Side Effects
Pediatric patients: dyspepsia, decreased appetite, headache, and anxiety. Adults: dry mouth, dyspepsia, headache, pharyngolaryngeal pain, and anxiety. Dose-related increases in psychiatric disorders (insomnia, depression) occur at higher doses.
Interactions
MAOIs can cause hypertensive crisis with potentially fatal outcomes. Antihypertensives may have reduced effectiveness. Avoid halogenated anesthetics on surgery day.
Warnings
CNS stimulants have a high potential for abuse and dependence. Sudden cardiac death in pediatric patients with structural cardiac abnormalities; blood pressure and heart rate increases; psychiatric adverse reactions including psychotic or manic symptoms; priapism; peripheral vasculopathy; and long-term growth suppression. Contraindicated with MAOIs or within 14 days due to hypertensive crisis risk.
Pregnancy
Published studies on methylphenidate use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse outcomes. However, CNS stimulants may cause vasoconstriction affecting placental perfusion.
Frequently Asked Questions
What is Dexmethylphenidate Hydrochloride used for?▼
Indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older as a central nervous system stimulant.
What are the side effects of Dexmethylphenidate Hydrochloride?▼
Pediatric patients: dyspepsia, decreased appetite, headache, and anxiety. Adults: dry mouth, dyspepsia, headache, pharyngolaryngeal pain, and anxiety. Dose-related increases in psychiatric disorders (insomnia, depression) occur at higher doses.
Can I take Dexmethylphenidate Hydrochloride during pregnancy?▼
Published studies on methylphenidate use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse outcomes. However, CNS stimulants may cause vasoconstriction affecting placental perfusion.
What are the important warnings for Dexmethylphenidate Hydrochloride?▼
CNS stimulants have a high potential for abuse and dependence. Sudden cardiac death in pediatric patients with structural cardiac abnormalities; blood pressure and heart rate increases; psychiatric adverse reactions including psychotic or manic symptoms; priapism; peripheral vasculopathy; and long-term growth suppression. Contraindicated with MAOIs or within 14 days due to hypertensive crisis risk.
Related Medications
Risankizumbab
risankizumbab
Dosage form: LIQUID. Active ingredients: RISANKIZUMAB (150 mg/150mg). Category: BULK INGREDIENT.
Ixazomib
ixazomib
11 DESCRIPTION Ixazomib is a proteasome inhibitor. Ixazomib citrate, a prodrug, rapidly hydrolyzes under physiological conditions to its biologically active form, ixazomib. The chemical name of ixazomib citrate is 1,3,2-dioxaborolane-4,4-diacetic acid, 2-[(1 R )-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo- and the structural formula is: The molecular formula for ixazomib citrate is C 20 H 23 BCl 2 N 2 O 9 and its molecular weight is 517.12.
Carbon Disulfide
carbon disulfide
Skin rash with tingling*
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.